Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis.
Diffuse parenchymal lung disease
Idiopathic pulmonary fibrosis
Interstitial lung disease
Progressive pulmonary fibrosis
Journal
Immunology and allergy clinics of North America
ISSN: 1557-8607
Titre abrégé: Immunol Allergy Clin North Am
Pays: United States
ID NLM: 8805635
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
medline:
17
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
ppublish
Résumé
Idiopathic pulmonary fibrosis (IPF), a common interstitial lung disease (ILD), is a chronic, progressive fibrosing interstitial pneumonia, with an unknown cause. IPF has been linked to several genetic and environmental risk factors. Disease progression is common and associated with worse outcomes. Management often encompasses pharmacotherapy, supportive interventions, addressing comorbidities when present, and treating hypoxia with ambulatory O2. Consideration for antifibrotic therapy and lung transplantation evaluation should occur early. Patients with ILD other than IPF, and who have radiological evidence of pulmonary fibrosis, may have progressive pulmonary fibrosis.
Identifiants
pubmed: 37055085
pii: S0889-8561(23)00010-3
doi: 10.1016/j.iac.2023.01.010
pii:
doi:
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
209-228Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL146942
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.